Lilly Plans ‘Big, Bold’ Launch For Zepbound
Lilly expects the obesity drug will be fully accessible in a therapeutic area that has experienced short supply. The list price will be 20% lower than the price of Wegovy.
You may also be interested in...
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.
With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.